Lexeo Therapeutics (LXEO) Total Liabilities (2022 - 2026)

Lexeo Therapeutics' Total Liabilities history runs 5 years deep, the most recent figure standing at $18.9 million for Q1 2026.

• In Q1 2026, Total Liabilities fell 49.81% year-over-year to $18.9 million; the TTM figure through Mar 2026 stood at $18.9 million (down 49.81% YoY), while the FY2025 annual figure was $22.0 million, down 26.85% from the prior year.
• Total Liabilities came in at $18.9 million for Q1 2026 at Lexeo Therapeutics, down from $22.0 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $143.6 million in Q2 2023 to a low of $18.9 million in Q1 2026.
• A 5-year average of $47.9 million and a median of $30.3 million in 2024 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities slumped 81.16% in 2024 and soared 39.88% in 2025, its largest moves.
• Lexeo Therapeutics' Total Liabilities stood at $25.0 million in 2022, then climbed by 5.1% to $26.3 million in 2023, then increased by 14.57% to $30.1 million in 2024, then declined by 26.85% to $22.0 million in 2025, then decreased by 14.35% to $18.9 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $18.9 million, $22.0 million, and $23.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison